lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Psychotherapy involves a formal relationship between professional and client—usually an individual, couple, family, or small group—that employs a set of procedures intended to form a therapeutic alliance, explore the nature of psychological problems, and encourage new ways of thinking, feeling, or behaving. Clinicians have a wide range of individual interventions to draw from, often guided by their training—for example, a cognitive behavioral therapy (CBT) clinician might use worksheets to record distressing cognitions, a psychoanalyst might encourage free association, while a psychologist trained in Gestalt techniques might focus on immediate interactions between client and therapist. Clinical psychologists generally seek to base their work on research evidence and outcome studies as well as on trained clinical judgment. Although there are literally dozens of recognized therapeutic orientations, their differences can often be categorized on two dimensions: insight vs. action and in-session vs. out-session.
== Chemical structure == The synthesis of CP-154,526, a non-peptide antagonist of the CRH1 receptor, was first described in 1997. Antalarmin is a close analog that is highly structurally similar and has been shown to be easier to synthesize. The findings from several chemical, pharmacokinetic and pharmacological studies indicate that the two compounds possess very similar properties.
==== Examples of metabolism-based interactions ==== An example of this is shown in the following table for the CYP1A2 enzyme, showing the substrates (drugs metabolized by this enzyme) and some inductors and inhibitors of its activity:
Similarly, a base such as spermine has more than one site where protonation can occur. For example, mono-protonation can occur at a terminal −NH2 group or at internal −NH− groups. The Kb values for dissociation of spermine protonated at one or other of the sites are examples of micro-constants. They cannot be determined directly by means of pH, absorbance, fluorescence or NMR measurements; a measured Kb value is the sum of the K values for the micro-reactions.
=== Stem cell === Chorionic villi are a rich source of stem cells. Biocell Center, a biotech company managed by Giuseppe Simoni, is studying and testing these types of stem cells. Chorionic stem cells, like amniotic stem cells, are uncontroversial multipotent stem cells.
Sources: en.wikipedia.org
==== Timber rattlesnake ==== The timber rattlesnake, (Crotalus horridus), is a species of venomous pit viper endemic to eastern North America. This is the only rattlesnake species in most of the populous northeastern United States and is second only to its cousins to the west, the prairie rattlesnake, as the most northerly distributed venomous snake in North America. No subspecies are currently recognized.
examine the system of local government in the areas of local government north and south of the river Tyne from the sea to the boundary of the Rural District of Castle Ward and Hexham in the County of Northumberland and to the Western boundary of the County of Durham, to consider what changes, if any, should be made in the existing arrangements with a view to securing greater economy and efficiency, and to make recommendations.
=== Resource use === Hydroponic systems use less water than traditional farming due to the system's ability to recirculate water rather than absorb it from the soil or lose it to evaporation. Nutrients are also efficiently delivered to plant roots, minimizing nutrient waste and lowering the cost of fertilizing crops.
During the work carried out in 1967 for the construction of the shopping arcade in the "Centre Bourse" in the heart of Marseille, important archaeological remains were unearthed. The extent of this discovery, which concerned the Greek fortifications of Marseille, funerary enclosures and part of the old port, necessitated the classification of approximately 10,000 m2 (110,000 sq ft) as a historical monument. The remaining area, of about 20,000 m2 (220,000 sq ft), was sacrificed to enable the construction of the Centre Bourse. The excavation lasted ten years and was carried out by the Antiquités historiques and the CNRS. Additional works were carried out later, particularly in 1994. It is in fact a contact area between on the one hand the ancient city which was located north of the current old port and included the hill of Saint-Jean Saint-Laurent, the Place des Moulins and the hill of Carmes, and on the other hand a suburban and port area outside the ramparts. A garden, surrounded on three sides by the shopping centre, has been laid out to highlight the vestiges, the results of one of the most important post-war urban excavations carried out in France. The objects discovered are on display at the Marseille History Museum.
Angiolymphoid hyperplasia with eosinophilia (epithelioid hemangioma, histiocytoid hemangioma, inflammatory angiomatous nodule, inflammatory arteriovenous hemangioma, intravenous atypical vascular proliferation, papular angioplasia, pseudopyogenic granuloma) Annular erythema of infancy Arthropod assault Eosinophilic cellulitis (Wells' syndrome) Eosinophilic fasciitis (Shulman's syndrome) Eosinophilic granuloma Eosinophilic granulomatosis with polyangiitis Eosinophilic pustular folliculitis of infancy (eosinophilic pustular folliculitis in infancy, infantile eosinophilic pustular folliculitis, neonatal eosinophilic pustular folliculitis) Eosinophilic ulcer of the oral mucosa (eosinophilic ulcer of the tongue, Riga–Fede disease, traumatic eosinophilic granuloma) Eosinophilic vasculitis Erythema toxicum neonatorum (erythema toxicum, toxic erythema of the newborn) Granuloma faciale Hypereosinophilia Hypereosinophilic syndrome Incontinentia pigmenti (Bloch–Siemens syndrome, Bloch–Sulzberger disease, Bloch–Sulzberger syndrome) Itchy red bump disease (papular dermatitis) Juvenile xanthogranuloma Kimura's disease Nodules–eosinophilia–rheumatism–dermatitis–swelling syndrome Pachydermatous eosinophilic dermatitis Papular eruption of blacks Papuloerythroderma of Ofuji Pruritic papular eruption of HIV disease
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.